Latest from Stephenson Cancer Center

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.
Kathleen Moore, MD, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.
We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.
Kathleen G. Essel, MD, discusses the rationale to explore quantitative computed tomography image feature analysis in gynecologic cancers.
Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.
Kathleen N. Moore, MD, discusses the potential impact of antibody-drug conjugates on outcomes for patients with ovarian cancer.
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.
The Stephenson Cancer Center, located in Oklahoma City, is a dynamic, rapidly evolving institution with a broad research and treatment portfolio currently pursuing NCI designation.
Publication Bottom Border
Border Publication